Pediatric cancer drug development
Search documents
Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025
Globenewswire· 2025-10-21 12:30
Company Overview - Day One Biopharmaceuticals is focused on developing and commercializing targeted therapies for life-threatening diseases, particularly in pediatric cancer [3][4] - The company aims to address the critical unmet need in pediatric cancer therapeutic development, inspired by the initial conversations between physicians and families regarding cancer diagnosis and treatment [3] Upcoming Events - Day One will host a live conference call and webcast on November 4, 2025, at 4:30 p.m. ET to report its financial results and discuss corporate progress for Q3 2025 [1] - The live audio of the webcast will be accessible on the company's Media & Investors page, with an archived version available for replay for 30 days post-event [2] Pipeline and Partnerships - Day One's pipeline includes targeted cancer treatments such as tovorafenib (OJEMDA™) and DAY301 [4] - The company collaborates with leading clinical oncologists, families, and scientists to identify, acquire, and develop important cancer treatments [4]
Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025
Globenewswire· 2025-07-22 12:30
Company Overview - Day One Biopharmaceuticals is focused on developing and commercializing targeted therapies for life-threatening diseases, particularly in pediatric cancer [3][4] - The company aims to address the critical unmet need in pediatric cancer therapeutic development, inspired by the initial conversations between physicians and families regarding cancer diagnosis and treatment [3] Upcoming Events - Day One will host a live conference call and webcast on August 5, 2025, at 4:30 p.m. ET to report its financial results and discuss corporate progress for the second quarter of 2025 [1] - The live audio of the webcast will be accessible on the company's Media & Investors page, with an archived version available for replay for 30 days following the event [2] Pipeline and Partnerships - The company's pipeline includes targeted cancer treatments such as tovorafenib (OJEMDA™) and DAY301 [4] - Day One collaborates with leading clinical oncologists, families, and scientists to identify, acquire, and develop important cancer treatments [4] Communication Channels - Day One utilizes its Investor Relations website, social media platforms, and other channels to disseminate news, announcements, and financial performance updates [5]